Cargando…
New developments in the treatment of hyperammonemia: emerging use of carglumic acid
Hyperammonemia is a true neonatal emergency with high toxicity for the central nervous system and developmental delay. The causes of neonatal hyperammonemia are genetic defects of urea cycle enzymes, organic acidemias, lysinuric protein intolerance, hyperammonemia–hyperornithinemia– homocitrullinemi...
Autores principales: | Daniotti, Marta, la Marca, Giancarlo, Fiorini, Patrizio, Filippi, Luca |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056327/ https://www.ncbi.nlm.nih.gov/pubmed/21403788 http://dx.doi.org/10.2147/IJGM.S10490 |
Ejemplares similares
Ejemplares similares
-
Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia?
por: Levrat, Virginie, et al.
Publicado: (2008) -
Use of carglumic acid in valproate‐induced hyperammonemia: 25 pediatric cases
por: Palomino Pérez, Laura María, et al.
Publicado: (2020) -
Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency
por: Häberle, Johannes
Publicado: (2011) -
Carglumic Acid Treatment of a Patient with Recurrent Valproic Acid-induced Hyperammonemia: A Rare Case Report
por: Sattar, Yasar, et al.
Publicado: (2018) -
Two Siblings With Valproate-Related Hyperammonemia and Novel Mutations in Glutamine Synthetase (GLUL) Treated With Carglumic Acid
por: Bennett, Jennifer, et al.
Publicado: (2020)